Resource impact summary report
Resource impact summary report
This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect local data and assumptions.
Recommendation
NICE has recommended capivasertib with fulvestrant for hormone receptor (HR)-positive HER2-negative (defined as immunohistochemistry [IHC]0 or IHC1 positive, or IHC2 positive and in situ hybridisation [ISH]1 negative) locally advanced or metastatic breast cancer in adults that has:
-
1 or more PIK3CA, AKT1 or PTEN gene alterations
-
recurred or progressed after a CDK 4 and 6 inhibitor plus an aromatase inhibitor.
Capivasertib plus fulvestrant is only recommended if the company provides it according to the commercial arrangement.
Eligible population for capivasertib
Table 1 shows the population who are eligible for capivasertib with fulvestrant and the number of people who are expected to have capivasertib with fulvestrant in each of the next 5 years.
| Eligible population and uptake | People eligible for capivasertib with fulvestrant | Uptake for capivasertib with fulvestrant (%) | People having capivasertib with fulvestrant each year |
|---|---|---|---|
|
Current practice |
1,110 |
0 |
0 |
|
Year 1 |
1,120 |
30 |
340 |
|
Year 2 |
1,140 |
40 |
450 |
|
Year 3 |
1,150 |
50 |
570 |
|
Year 4 |
1,160 |
50 |
580 |
|
Year 5 |
1,170 |
50 |
580 |
The uptake for capivasertib with fulvestrant is based on clinical expert opinion.
Treatment options for the eligible population
The comparator treatments for the eligible population are alpelisib with fulvestrant and everolimus with exemestane. Capivasertib with fulvestrant and alpelisib with fulvestrant are both combinations of oral tablets and fulvestrant intramuscular injections. Everolimus with exemestane is an oral-only treatment option.
For more information about the treatments, such as dose and average treatment duration, see the resource impact template.
Financial resource impact (cash items)
The company has a commercial arrangement. This makes capivasertib available to the NHS with a discount.
Users can input the confidential price of capivasertib and amend other variables in the resource impact template.
The payment mechanism for the technology is determined by the responsible commissioner and depends on the technology being classified as high cost.
For further analysis or to calculate the financial impact of cash items, see the resource impact template.
Capacity impact
Table 2 shows the impact on capacity activity in each of the next 5 years.
| Capacity impact | Number of intramuscular injections |
|---|---|
|
Current year |
1,940 |
|
Year 1 |
3,880 |
|
Year 2 |
4,620 |
|
Year 3 |
5,380 |
|
Year 4 |
5,430 |
|
Year 5 |
5,480 |
For further analysis or to calculate the financial capacity impact from a commissioner (national) and provider (local) perspective, see the resource impact template.
Key information
Table 3 Key information| Time from publication to routine commissioning funding |
90 days |
|---|---|
| Programme budgeting category |
02F, cancers and tumours, breast |
| Commissioner(s) |
NHS England |
| Provider(s) |
NHS hospital trusts |
| Pathway position |
Second line |
About this resource impact summary report
This resource impact summary report accompanies the NICE technology appraisal guidance on capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment and should be read with it.
ISBN: 978-1-4731-7025-4
This page was last updated: